ID   M3K9_HUMAN              Reviewed;        1104 AA.
AC   P80192; A3KN85; Q0D2G7; Q6EH31; Q9H2N5;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   15-MAR-2017, entry version 168.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 9;
DE            EC=2.7.11.25;
DE   AltName: Full=Mixed lineage kinase 1;
GN   Name=MAP3K9; Synonyms=MLK1, PRKE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ENZYME REGULATION,
RP   PHOSPHORYLATION AT THR-304; THR-305; SER-308 AND THR-312, AND
RP   MUTAGENESIS OF LYS-171; THR-304; THR-305; SER-308 AND THR-312.
RX   PubMed=15610029; DOI=10.1021/bi049866y;
RA   Durkin J.T., Holskin B.P., Kopec K.K., Reed M.S., Spais C.M.,
RA   Steffy B.M., Gessner G., Angeles T.S., Pohl J., Ator M.A., Meyer S.L.;
RT   "Phosphoregulation of mixed-lineage kinase 1 activity by multiple
RT   phosphorylation in the activation loop.";
RL   Biochemistry 43:16348-16355(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 53-1104 (ISOFORM 2).
RA   McNee J.J., Dower S.K., Guesdon F.;
RT   "cDNA sequence and gene organisation of mixed lineage kinase 1.";
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 142-535, AND TISSUE SPECIFICITY.
RC   TISSUE=Colon epithelium;
RX   PubMed=8477742; DOI=10.1111/j.1432-1033.1993.tb17810.x;
RA   Dorow D.S., Devereux L., Dietzsch E., de Kretser T.;
RT   "Identification of a new family of human epithelial protein kinases
RT   containing two leucine/isoleucine-zipper domains.";
RL   Eur. J. Biochem. 213:701-710(1993).
RN   [5]
RP   ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND PHOSPHORYLATION
RP   OF MAP2K4/MKK4.
RX   PubMed=11325962; DOI=10.1074/jbc.M011601200;
RA   Maroney A.C., Finn J.P., Connors T.J., Durkin J.T., Angeles T.,
RA   Gessner G., Xu Z., Meyer S.L., Savage M.J., Greene L.A., Scott R.W.,
RA   Vaught J.L.;
RT   "Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage
RT   kinase family.";
RL   J. Biol. Chem. 276:25302-25308(2001).
RN   [6]
RP   FUNCTION IN THE APOPTOSIS PATHWAY.
RX   PubMed=11416147; DOI=10.1128/MCB.21.14.4713-4724.2001;
RA   Xu Z., Maroney A.C., Dobrzanski P., Kukekov N.V., Greene L.A.;
RT   "The MLK family mediates c-Jun N-terminal kinase activation in
RT   neuronal apoptosis.";
RL   Mol. Cell. Biol. 21:4713-4724(2001).
RN   [7]
RP   ENZYME REGULATION.
RX   PubMed=11755341; DOI=10.1016/S0960-894X(01)00690-4;
RA   Murakata C., Kaneko M., Gessner G., Angeles T.S., Ator M.A.,
RA   O'Kane T.M., McKenna B.A., Thomas B.A., Mathiasen J.R., Saporito M.S.,
RA   Bozyczko-Coyne D., Hudkins R.L.;
RT   "Mixed lineage kinase activity of indolocarbazole analogues.";
RL   Bioorg. Med. Chem. Lett. 12:147-150(2002).
RN   [8]
RP   POSSIBLE ROLE IN ESOPHAGEAL CANCER.
RX   PubMed=18241037; DOI=10.1002/ijc.23397;
RA   Chen J., Guo L., Peiffer D.A., Zhou L., Chan O.T., Bibikova M.,
RA   Wickham-Garcia E., Lu S.H., Zhan Q., Wang-Rodriguez J., Jiang W.,
RA   Fan J.B.;
RT   "Genomic profiling of 766 cancer-related genes in archived esophageal
RT   normal and carcinoma tissues.";
RL   Int. J. Cancer 122:2249-2254(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 136-406.
RX   PubMed=18714982; DOI=10.1021/jm8005838;
RA   Hudkins R.L., Diebold J.L., Tao M., Josef K.A., Park C.H.,
RA   Angeles T.S., Aimone L.D., Husten J., Ator M.A., Meyer S.L.,
RA   Holskin B.P., Durkin J.T., Fedorov A.A., Fedorov E.V., Almo S.C.,
RA   Mathiasen J.R., Bozyczko-Coyne D., Saporito M.S., Scott R.W.,
RA   Mallamo J.P.;
RT   "Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective
RT   dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization,
RT   mixed-lineage kinase 1 crystallography, and oral in vivo activity in
RT   1-methyl-4-phenyltetrahydropyridine models.";
RL   J. Med. Chem. 51:5680-5689(2008).
RN   [12]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-246; CYS-467; GLN-497 AND CYS-646.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase which acts as an essential
CC       component of the MAP kinase signal transduction pathway. Plays an
CC       important role in the cascades of cellular responses evoked by
CC       changes in the environment. Once activated, acts as an upstream
CC       activator of the MKK/JNK signal transduction cascade through the
CC       phosphorylation of MAP2K4/MKK4 and MAP2K7/MKK7 which in turn
CC       activate the JNKs. The MKK/JNK signaling pathway regulates stress
CC       response via activator protein-1 (JUN) and GATA4 transcription
CC       factors. Plays also a role in mitochondrial death signaling
CC       pathway, including the release cytochrome c, leading to apoptosis.
CC       {ECO:0000269|PubMed:11416147, ECO:0000269|PubMed:15610029}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Homodimerization via the leucine zipper domains
CC       is required for autophosphorylation of multiple sites in the
CC       activation loop and subsequent activation. Autophosphorylation at
CC       Thr-312 is the key step in activation of MAP3K9/MLK1 and is
CC       required for full phosphorylation. Autophosphorylation at Thr-304
CC       and Ser-308 have been shown to be of secondary importance in the
CC       activation of MAP3K9/MLK1. CEP-1347 and many indolocarbazole
CC       analogs have been shown to act as inhibitors of MAP3K9/MLK1
CC       activity. {ECO:0000269|PubMed:11325962,
CC       ECO:0000269|PubMed:11755341, ECO:0000269|PubMed:15610029}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=62 uM for ATP {ECO:0000269|PubMed:11325962};
CC         KM=7 uM for myelin basic protein (MBP) as substrate
CC         {ECO:0000269|PubMed:11325962};
CC   -!- SUBUNIT: Homodimer. {ECO:0000250}.
CC   -!- INTERACTION:
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-3951604, EBI-352572;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P80192-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P80192-4; Sequence=VSP_013765;
CC   -!- TISSUE SPECIFICITY: Expressed in epithelial tumor cell lines of
CC       colonic, breast and esophageal origin.
CC       {ECO:0000269|PubMed:8477742}.
CC   -!- PTM: Autophosphorylation on serine and threonine residues within
CC       the activation loop plays a role in enzyme activation. Thr-312 is
CC       likely to be the main autophosphorylation site.
CC       Autophosphorylation also occurs on Thr-304 and Ser-308.
CC       {ECO:0000269|PubMed:11325962, ECO:0000269|PubMed:15610029}.
CC   -!- DISEASE: Note=May play a role in esophageal cancer susceptibility
CC       and/or development.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAI11408.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY327900; AAQ23054.1; -; mRNA.
DR   EMBL; BC111407; AAI11408.1; ALT_INIT; mRNA.
DR   EMBL; BC133706; AAI33707.1; -; mRNA.
DR   EMBL; AF251442; AAG44591.1; -; mRNA.
DR   CCDS; CCDS32112.1; -. [P80192-4]
DR   CCDS; CCDS61488.1; -. [P80192-1]
DR   PIR; S32467; JU0229.
DR   RefSeq; NP_001271159.1; NM_001284230.1. [P80192-1]
DR   RefSeq; NP_149132.2; NM_033141.3. [P80192-4]
DR   UniGene; Hs.445496; -.
DR   UniGene; Hs.593542; -.
DR   PDB; 3DTC; X-ray; 2.60 A; A=136-406.
DR   PDB; 4UY9; X-ray; 2.81 A; A/B=135-456.
DR   PDBsum; 3DTC; -.
DR   PDBsum; 4UY9; -.
DR   ProteinModelPortal; P80192; -.
DR   SMR; P80192; -.
DR   BioGrid; 110439; 2.
DR   IntAct; P80192; 1.
DR   STRING; 9606.ENSP00000451263; -.
DR   BindingDB; P80192; -.
DR   ChEMBL; CHEMBL2872; -.
DR   GuidetoPHARMACOLOGY; 2084; -.
DR   iPTMnet; P80192; -.
DR   PhosphoSitePlus; P80192; -.
DR   DMDM; 116242625; -.
DR   PaxDb; P80192; -.
DR   PeptideAtlas; P80192; -.
DR   PRIDE; P80192; -.
DR   Ensembl; ENST00000554752; ENSP00000451612; ENSG00000006432. [P80192-1]
DR   Ensembl; ENST00000555993; ENSP00000451263; ENSG00000006432. [P80192-4]
DR   GeneID; 4293; -.
DR   KEGG; hsa:4293; -.
DR   UCSC; uc001xml.5; human. [P80192-1]
DR   CTD; 4293; -.
DR   DisGeNET; 4293; -.
DR   GeneCards; MAP3K9; -.
DR   H-InvDB; HIX0011779; -.
DR   HGNC; HGNC:6861; MAP3K9.
DR   HPA; HPA000942; -.
DR   MIM; 600136; gene.
DR   neXtProt; NX_P80192; -.
DR   OpenTargets; ENSG00000006432; -.
DR   PharmGKB; PA30607; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118807; -.
DR   HOGENOM; HOG000060081; -.
DR   HOVERGEN; HBG067662; -.
DR   InParanoid; P80192; -.
DR   KO; K04417; -.
DR   OMA; HHRRCEV; -.
DR   OrthoDB; EOG091G0JNI; -.
DR   PhylomeDB; P80192; -.
DR   TreeFam; TF105118; -.
DR   SignaLink; P80192; -.
DR   SIGNOR; P80192; -.
DR   ChiTaRS; MAP3K9; human.
DR   EvolutionaryTrace; P80192; -.
DR   GeneWiki; MAP3K9; -.
DR   GenomeRNAi; 4293; -.
DR   PRO; PR:P80192; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000006432; -.
DR   CleanEx; HS_MAP3K9; -.
DR   ExpressionAtlas; P80192; baseline and differential.
DR   Genevisible; P80192; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004706; F:JUN kinase kinase kinase activity; ISS:UniProtKB.
DR   GO; GO:0004708; F:MAP kinase kinase activity; NAS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007257; P:activation of JUN kinase activity; ISS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR016231; MLK1/MLK2/MLK4.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR001452; SH3_domain.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF14604; SH3_9; 1.
DR   PIRSF; PIRSF000556; MAPKKK9_11; 1.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Complete proteome; Kinase; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; SH3 domain; Stress response;
KW   Transcription; Transcription regulation; Transferase.
FT   CHAIN         1   1104       Mitogen-activated protein kinase kinase
FT                                kinase 9.
FT                                /FTId=PRO_0000086258.
FT   DOMAIN       52    116       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      144    412       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     150    158       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      430    451       Leucine-zipper 1.
FT   REGION      465    486       Leucine-zipper 2.
FT   COMPBIAS     12     42       Ala-rich.
FT   COMPBIAS     30     38       Poly-Glu.
FT   COMPBIAS    495    509       Arg/Lys-rich (basic).
FT   COMPBIAS    863    972       Pro-rich.
FT   COMPBIAS   1011   1041       Ser-rich.
FT   ACT_SITE    268    268       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     171    171       ATP.
FT   MOD_RES     304    304       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15610029}.
FT   MOD_RES     305    305       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15610029}.
FT   MOD_RES     308    308       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15610029}.
FT   MOD_RES     312    312       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15610029}.
FT   MOD_RES     533    533       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     675    675       M -> MALLAASWVVPIDIE (in isoform 2).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_013765.
FT   VARIANT     246    246       A -> V (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040698.
FT   VARIANT     467    467       R -> C (in a gastric adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs773256562).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040699.
FT   VARIANT     497    497       R -> Q (in dbSNP:rs56196343).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040700.
FT   VARIANT     646    646       Y -> C (in dbSNP:rs34322726).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040701.
FT   MUTAGEN     171    171       K->A: Loss of kinase activity and
FT                                threonine phosphorylation.
FT                                {ECO:0000269|PubMed:15610029}.
FT   MUTAGEN     304    304       T->A: Reduces threonine phosphorylation.
FT                                Impairs JNK activation.
FT                                {ECO:0000269|PubMed:15610029}.
FT   MUTAGEN     305    305       T->A: Little effect on threonine
FT                                phosphorylation. Mildly impairs JNK
FT                                activation.
FT                                {ECO:0000269|PubMed:15610029}.
FT   MUTAGEN     308    308       S->A: Impairs JNK activation.
FT                                {ECO:0000269|PubMed:15610029}.
FT   MUTAGEN     312    312       T->A: Loss of threonine phosphorylation.
FT                                Strongly impairs JNK activation.
FT                                {ECO:0000269|PubMed:15610029}.
FT   CONFLICT    356    356       A -> R (in Ref. 4). {ECO:0000305}.
FT   CONFLICT    433    433       M -> T (in Ref. 1; AAQ23054).
FT                                {ECO:0000305}.
FT   CONFLICT    511    535       KLKDGNRISLPSDFQHKFTVQASPT -> AQPVLPFPHGHS
FT                                RCPGGTGSSWGGQ (in Ref. 4). {ECO:0000305}.
FT   STRAND      143    153       {ECO:0000244|PDB:3DTC}.
FT   STRAND      156    163       {ECO:0000244|PDB:3DTC}.
FT   STRAND      166    172       {ECO:0000244|PDB:3DTC}.
FT   HELIX       185    197       {ECO:0000244|PDB:3DTC}.
FT   STRAND      206    210       {ECO:0000244|PDB:3DTC}.
FT   STRAND      217    221       {ECO:0000244|PDB:3DTC}.
FT   HELIX       228    232       {ECO:0000244|PDB:3DTC}.
FT   HELIX       239    258       {ECO:0000244|PDB:3DTC}.
FT   STRAND      259    262       {ECO:0000244|PDB:3DTC}.
FT   HELIX       271    273       {ECO:0000244|PDB:3DTC}.
FT   STRAND      274    278       {ECO:0000244|PDB:3DTC}.
FT   STRAND      281    283       {ECO:0000244|PDB:3DTC}.
FT   STRAND      290    292       {ECO:0000244|PDB:3DTC}.
FT   HELIX       299    301       {ECO:0000244|PDB:4UY9}.
FT   HELIX       313    315       {ECO:0000244|PDB:3DTC}.
FT   HELIX       318    323       {ECO:0000244|PDB:3DTC}.
FT   HELIX       328    344       {ECO:0000244|PDB:3DTC}.
FT   TURN        348    351       {ECO:0000244|PDB:3DTC}.
FT   HELIX       354    362       {ECO:0000244|PDB:3DTC}.
FT   HELIX       376    385       {ECO:0000244|PDB:3DTC}.
FT   HELIX       390    392       {ECO:0000244|PDB:3DTC}.
FT   HELIX       396    404       {ECO:0000244|PDB:3DTC}.
FT   HELIX       410    412       {ECO:0000244|PDB:4UY9}.
FT   HELIX       418    439       {ECO:0000244|PDB:4UY9}.
FT   HELIX       441    444       {ECO:0000244|PDB:4UY9}.
SQ   SEQUENCE   1104 AA;  121895 MW;  0F059C867FCE7276 CRC64;
     MEPSRALLGC LASAAAAAPP GEDGAGAGAE EEEEEEEEAA AAVGPGELGC DAPLPYWTAV
     FEYEAAGEDE LTLRLGDVVE VLSKDSQVSG DEGWWTGQLN QRVGIFPSNY VTPRSAFSSR
     CQPGGEDPSC YPPIQLLEID FAELTLEEII GIGGFGKVYR AFWIGDEVAV KAARHDPDED
     ISQTIENVRQ EAKLFAMLKH PNIIALRGVC LKEPNLCLVM EFARGGPLNR VLSGKRIPPD
     ILVNWAVQIA RGMNYLHDEA IVPIIHRDLK SSNILILQKV ENGDLSNKIL KITDFGLARE
     WHRTTKMSAA GTYAWMAPEV IRASMFSKGS DVWSYGVLLW ELLTGEVPFR GIDGLAVAYG
     VAMNKLALPI PSTCPEPFAK LMEDCWNPDP HSRPSFTNIL DQLTTIEESG FFEMPKDSFH
     CLQDNWKHEI QEMFDQLRAK EKELRTWEEE LTRAALQQKN QEELLRRREQ ELAEREIDIL
     ERELNIIIHQ LCQEKPRVKK RKGKFRKSRL KLKDGNRISL PSDFQHKFTV QASPTMDKRK
     SLINSRSSPP ASPTIIPRLR AIQLTPGESS KTWGRSSVVP KEEGEEEEKR APKKKGRTWG
     PGTLGQKELA SGDEGSPQRR EKANGLSTPS ESPHFHLGLK SLVDGYKQWS SSAPNLVKGP
     RSSPALPGFT SLMEMEDEDS EGPGSGESRL QHSPSQSYLC IPFPRGEDGD GPSSDGIHEE
     PTPVNSATST PQLTPTNSLK RGGAHHRRCE VALLGCGAVL AATGLGFDLL EAGKCQLLPL
     EEPEPPAREE KKRREGLFQR SSRPRRSTSP PSRKLFKKEE PMLLLGDPSA SLTLLSLSSI
     SECNSTRSLL RSDSDEIVVY EMPVSPVEAP PLSPCTHNPL VNVRVERFKR DPNQSLTPTH
     VTLTTPSQPS SHRRTPSDGA LKPETLLASR SPSSNGLSPS PGAGMLKTPS PSRDPGEFPR
     LPDPNVVFPP TPRRWNTQQD STLERPKTLE FLPRPRPSAN RQRLDPWWFV SPSHARSTSP
     ANSSSTETPS NLDSCFASSS STVEERPGLP ALLPFQAGPL PPTERTLLDL DAEGQSQDST
     VPLCRAELNT HRPAPYEIQQ EFWS
//
